We are concerned that Germany, Japan, and other high-income countries continue to maintain policies inconsistent with the Administration’s objective that U.S. trading partners pay their fair share for pharmaceutical innovation.
Senator Young addressing foreign pharmaceutical pricing practices.
Share
More from Todd Young
We have a choice: do nothing and invite a potential economic and national security disaster… Or rebuild our fleet, end our dependance on Chinese ships, and open a new era of American shipbuilding."
I supported this legislation because the stakes are too high to stand still, and I will continue advocating for a transparent, disciplined approach to implementing these authorities.
One could imagine this issue being broadly bipartisan as well at a time when people rightly question whether there are just basic good government measures that we can take across party lines that majorities can agree to.
To remain the world’s technological leader, we need more American scientists and engineers.
Other voices in this conversation
